|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
KR20120059581A
(ko)
|
2009-08-24 |
2012-06-08 |
윌슨 울프 매뉴팩처링 |
다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ｃｔｌ주의 생성
|
|
KR102095670B1
(ko)
*
|
2010-05-14 |
2020-03-31 |
더 제너럴 하스피톨 코포레이션 |
종양 특이적 신생항원을 확인하는 조성물 및 방법
|
|
EP2714071B1
(en)
*
|
2011-05-24 |
2019-07-10 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
PL3892295T3
(pl)
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
JP6241735B2
(ja)
*
|
2011-08-02 |
2017-12-06 |
国立大学法人 東京大学 |
骨髄異形成症候群または骨髄性腫瘍の評価方法、そのポリペプチド及び抗体、並びにその治療薬若しくは予防薬の候補物スクリーニング方法
|
|
WO2013049750A1
(en)
*
|
2011-09-29 |
2013-04-04 |
Trovagene, Inc. |
Mutations in sf3b1 and chronic lymphocytic leukemia
|
|
US20140364439A1
(en)
*
|
2011-12-07 |
2014-12-11 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
EP2812431B1
(en)
|
2012-02-09 |
2019-07-17 |
Baylor College Of Medicine |
Pepmixes to generate multiviral ctls with broad specificity
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
AU2013266066A1
(en)
|
2012-05-25 |
2014-12-11 |
Agenus Inc. |
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing sHLA technology and complementary enrichment strategies
|
|
ES2729759T3
(es)
*
|
2012-07-12 |
2019-11-06 |
Persimmune Inc |
Vacunas contra el cáncer personalizadas y terapias celulares inmunitarias adoptivas
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
HK1212237A1
(en)
|
2012-08-31 |
2016-06-10 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
EP4088737A3
(en)
|
2012-09-05 |
2023-02-08 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
|
AU2013323368B2
(en)
*
|
2012-09-28 |
2019-03-21 |
The University Of Connecticut |
Identification of tumor-protective epitopes for the treatment of cancers
|
|
EP2925348B1
(en)
|
2012-11-28 |
2019-03-06 |
BioNTech RNA Pharmaceuticals GmbH |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
BR122021025267B1
(pt)
|
2013-02-22 |
2023-12-05 |
Curevac Ag |
Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
|
|
KR102164405B1
(ko)
|
2013-03-14 |
2020-10-12 |
더 존스 홉킨스 유니버시티 |
나노스케일 인공 항원 제시 세포
|
|
BR112015025460B1
(pt)
*
|
2013-04-07 |
2024-01-02 |
The Broad Institute, Inc. |
Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
JP6740127B2
(ja)
*
|
2013-12-06 |
2020-08-12 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
新生物ワクチン用製剤
|
|
NZ721908A
(en)
*
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
|
SG10201805674YA
(en)
*
|
2014-01-02 |
2018-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
EP3137100B1
(en)
|
2014-04-15 |
2023-12-20 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
JP2017528143A
(ja)
*
|
2014-09-10 |
2017-09-28 |
ザ ユニバーシティ オブ コネチカット |
癌の治療のための免疫防御ネオエピトープ同定
|
|
AU2015315005B9
(en)
*
|
2014-09-10 |
2021-08-12 |
Genentech, Inc. |
Immunogenic mutant peptide screening platform
|
|
EP3193892A4
(en)
*
|
2014-09-14 |
2018-09-12 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
US10987412B2
(en)
*
|
2014-09-17 |
2021-04-27 |
The John Hopkins University |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific T cells
|
|
SI3193917T1
(sl)
*
|
2014-09-17 |
2022-02-28 |
Io Biotech Aps |
Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
US10973894B2
(en)
|
2014-10-02 |
2021-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human |
Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
|
|
WO2016057898A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonist with checkpoint inhibitors
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP4636401A2
(en)
|
2014-12-19 |
2025-10-22 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
CA2979712C
(en)
*
|
2015-03-25 |
2024-01-23 |
The Regents Of The University Of Michigan |
Nanoparticle compositions for delivery of biomacromolecules
|
|
WO2016164833A1
(en)
*
|
2015-04-08 |
2016-10-13 |
Nantomics, Llc |
Cancer neoepitopes
|
|
RU2719033C2
(ru)
|
2015-04-23 |
2020-04-16 |
Нантомикс, Ллс |
Способ получения фармацевтического агента для иммунотерапии рака
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
ES2836273T3
(es)
*
|
2015-04-27 |
2021-06-24 |
Cancer Research Tech Ltd |
Método para el tratamiento del cáncer
|
|
WO2016179006A1
(en)
|
2015-05-01 |
2016-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
EP3294324A1
(en)
|
2015-05-13 |
2018-03-21 |
Agenus Inc. |
Vaccines for treatment and prevention of cancer
|
|
CA2986235A1
(en)
*
|
2015-05-20 |
2016-11-24 |
The Broad Institute, Inc. |
Shared neoantigens
|
|
TWI750122B
(zh)
*
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
EP3323070B1
(en)
|
2015-07-14 |
2024-05-08 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
WO2017020026A1
(en)
*
|
2015-07-30 |
2017-02-02 |
Modernatx, Inc. |
Concatemeric peptide epitopes rnas
|
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
IL298359B2
(en)
|
2015-09-18 |
2025-12-01 |
Baylor College Medicine |
Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
AU2016339924B2
(en)
*
|
2015-10-12 |
2020-01-02 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
KR20180087246A
(ko)
*
|
2015-10-12 |
2018-08-01 |
난토믹스, 엘엘씨 |
네오에피토프의 반복적 발견 및 이에 대한 적응성 면역치료 및 방법
|
|
EP3362929B1
(en)
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
CN108430456B
(zh)
|
2015-10-22 |
2022-01-18 |
摩登纳特斯有限公司 |
癌症疫苗
|
|
RU2743169C2
(ru)
|
2015-11-06 |
2021-02-15 |
Вентана Медикал Системз, Инк. |
Репрезентативная диагностика
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
KR102883915B1
(ko)
|
2015-12-16 |
2025-11-18 |
시애틀 프로젝트 코포레이션 |
신생항원 동정, 제조, 및 용도
|
|
WO2017112954A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by promoting premature termination codon read-through
|
|
KR102833333B1
(ko)
|
2016-01-08 |
2025-07-11 |
니코데 테라퓨틱스 에이에스에이 |
치료적 항암 네오에피토프 백신
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
AU2017217877A1
(en)
*
|
2016-02-12 |
2018-08-16 |
Nant Holdings Ip, Llc |
High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
JP2019511903A
(ja)
*
|
2016-02-19 |
2019-05-09 |
ナント ホールディングス アイピー エルエルシーＮａｎｔ Ｈｏｌｄｉｎｇｓ ＩＰ， ＬＬＣ |
免疫原性調節の方法
|
|
JP2019513021A
(ja)
*
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
WO2017177207A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene, Llc |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US20190062272A1
(en)
*
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
WO2017223085A2
(en)
|
2016-06-20 |
2017-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
EP3484448B1
(en)
|
2016-07-13 |
2025-04-09 |
President and Fellows of Harvard College |
Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
|
|
SG11201900132QA
(en)
*
|
2016-07-20 |
2019-02-27 |
Biontech Rna Pharmaceuticals Gmbh |
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
|
|
WO2018026914A1
(en)
*
|
2016-08-02 |
2018-02-08 |
Nantcell, Inc. |
Transfection of dendritic cells and methods therefor
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US20190237158A1
(en)
*
|
2016-08-31 |
2019-08-01 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
IL292658A
(en)
|
2016-09-15 |
2022-07-01 |
Idera Pharmaceuticals Inc |
Immune modulation with tlr9 agonists for cancer treatment
|
|
WO2018057447A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US20190240257A1
(en)
*
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
GB2573406B
(en)
*
|
2016-10-18 |
2021-11-10 |
Univ Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018089637A1
(en)
|
2016-11-11 |
2018-05-17 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
EP3548897A4
(en)
|
2016-12-01 |
2020-08-12 |
Nantomics, LLC |
PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
EP3576780A1
(en)
|
2017-02-01 |
2019-12-11 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
RU2768829C2
(ru)
*
|
2017-02-01 |
2022-03-24 |
МОДЕРНАТиЭкс, ИНК. |
Противораковые рнк-вакцины
|
|
BR112019019407A2
(pt)
*
|
2017-03-20 |
2020-05-26 |
Genocea Biosciences Inc. |
Métodos de tratamento
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
JP7457642B2
(ja)
|
2017-04-03 |
2024-03-28 |
ビオンテック ユーエス インコーポレイテッド |
タンパク質抗原およびその使用
|
|
CA3057715A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
EP3612965A4
(en)
*
|
2017-04-19 |
2021-01-13 |
Gritstone Oncology, Inc. |
NEOANTIGEN IDENTIFICATION, MANUFACTURING AND USE
|
|
CN116983395A
(zh)
|
2017-04-24 |
2023-11-03 |
河谷细胞有限公司 |
靶向性新表位载体及其方法
|
|
TW201907937A
(zh)
|
2017-05-08 |
2019-03-01 |
美商葛利史東腫瘤科技公司 |
阿爾法病毒新抗原載體
|
|
EP3622068B1
(en)
|
2017-05-10 |
2024-02-28 |
The Broad Institute, Inc. |
Methods for determination of mutations in single replication events
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
CN110996970A
(zh)
*
|
2017-06-02 |
2020-04-10 |
亚利桑那州立大学董事会 |
创建个性化癌症疫苗的方法
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
JP7334124B2
(ja)
*
|
2017-06-21 |
2023-08-28 |
トランジェーヌ |
個別化ワクチン
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
TWI832820B
(zh)
|
2017-07-21 |
2024-02-21 |
美商伯克利之光生命科技公司 |
抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
|
|
WO2019023269A1
(en)
|
2017-07-25 |
2019-01-31 |
California Institute Of Technology |
DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
CA3076918A1
(en)
*
|
2017-10-02 |
2019-04-11 |
Curematch, Inc. |
Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
|
|
US12195536B2
(en)
*
|
2017-10-06 |
2025-01-14 |
The Wistar Institute Of Anatomy And Biology |
DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer
|
|
WO2019075112A1
(en)
|
2017-10-10 |
2019-04-18 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
|
|
WO2019086711A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Ludwig Institute For Cancer Research Ltd |
Method for expansion of lymphocytes
|
|
WO2019094396A1
(en)
*
|
2017-11-07 |
2019-05-16 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
WO2019094642A1
(en)
|
2017-11-08 |
2019-05-16 |
Neon Therapeutics, Inc. |
T cell manufacturing compositions and methods
|
|
KR20260008173A
(ko)
|
2017-11-22 |
2026-01-15 |
시애틀 프로젝트 코포레이션 |
신생항원에 대한 접합 에피토프 제시 감소
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
US11793867B2
(en)
|
2017-12-18 |
2023-10-24 |
Biontech Us Inc. |
Neoantigens and uses thereof
|
|
JP7653013B2
(ja)
|
2018-01-04 |
2025-03-28 |
アイコニック セラピューティクス リミテッド ライアビリティ カンパニー |
抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法
|
|
CN111836639A
(zh)
|
2018-01-26 |
2020-10-27 |
河谷细胞有限公司 |
用于联合癌症疫苗和免疫辅助疗法的组合物和方法
|
|
US11573230B2
(en)
|
2018-01-26 |
2023-02-07 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
IL276839B1
(en)
*
|
2018-02-27 |
2026-05-01 |
Gritstone Bio Inc |
Neoantigen identification using pan-allelic models
|
|
KR20210005646A
(ko)
|
2018-04-26 |
2021-01-14 |
아게누스 인코포레이티드 |
열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
|
|
TW202000907A
(zh)
|
2018-05-23 |
2020-01-01 |
美商葛利史東腫瘤科技公司 |
共有抗原
|
|
MX2020012649A
(es)
*
|
2018-05-25 |
2021-07-02 |
The Wistar Inst |
Neoantígenos especificos de tumor y métodos de uso de estos.
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
WO2019246286A1
(en)
|
2018-06-19 |
2019-12-26 |
Neon Therapeutics, Inc. |
Neoantigens and uses thereof
|
|
US12005104B2
(en)
|
2018-07-26 |
2024-06-11 |
Curevac Netherlands B.V. |
Cancer vaccines for colorectal cancer
|
|
IL280112B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for breast cancer
|
|
WO2020022903A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
|
|
US20220349010A1
(en)
|
2018-07-26 |
2022-11-03 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
CA3106567A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
IL280113B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for uterine cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
SG11202101400UA
(en)
|
2018-08-31 |
2021-03-30 |
Guardant Health Inc |
Microsatellite instability detection in cell-free dna
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
CA3112813A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
JP7585195B2
(ja)
|
2018-09-27 |
2024-11-18 |
ナイコード セラピューティクス アルメン アクスイェ セルスカプ |
ネオエピトープを選択する方法
|
|
SG11202103296RA
(en)
|
2018-10-18 |
2021-05-28 |
Berkeley Lights Inc |
Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
|
|
KR20210095157A
(ko)
|
2018-11-08 |
2021-07-30 |
넥스이뮨, 인크. |
개선된 표현형 속성을 갖는 t 세포 조성물
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
CA3130750A1
(en)
|
2019-02-20 |
2020-08-27 |
Rubius Therapeutics, Inc. |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
US20220130489A1
(en)
*
|
2019-03-12 |
2022-04-28 |
Syntekabio,Inc. |
System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
|
|
WO2020227233A2
(en)
*
|
2019-05-03 |
2020-11-12 |
Richard Guilhem |
Neoantigens in cancer
|
|
US20220220472A1
(en)
*
|
2019-05-06 |
2022-07-14 |
The Regents Of The University Of Michigan |
Targeted therapy
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
EP4038222A4
(en)
|
2019-10-02 |
2023-10-18 |
Arizona Board of Regents on behalf of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
CA3173793A1
(en)
|
2020-04-03 |
2021-10-07 |
Andrew Ferguson |
Infectious disease antigens and vaccines
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
US20230212243A1
(en)
*
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
|
MX2022014249A
(es)
*
|
2020-05-12 |
2023-02-22 |
Sumitomo Pharma Co Ltd |
Composición farmacéutica para tratar el cáncer.
|
|
US20230210968A1
(en)
|
2020-06-11 |
2023-07-06 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
EP4192496A4
(en)
|
2020-08-06 |
2025-01-01 |
Gritstone bio, Inc. |
MULTIEPITOP VACCINE CASSETTES
|
|
IL300564A
(en)
|
2020-08-13 |
2023-04-01 |
Biontech Us Inc |
Preparations and methods for the production of T cells
|
|
CN116133682A
(zh)
*
|
2020-08-31 |
2023-05-16 |
环球生物科技再生医疗集团有限公司 |
个性化免疫原性组合物及其生产和使用方法
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
CN117479951A
(zh)
*
|
2021-03-26 |
2024-01-30 |
转化基因组学研究所 |
用于新抗原疫苗的方法和化合物
|
|
CN117321189A
(zh)
|
2021-04-30 |
2023-12-29 |
泰根制药有限公司 |
淋巴细胞的单血管扩增
|
|
CN117813108A
(zh)
*
|
2021-05-27 |
2024-04-02 |
亚马逊科技公司 |
基于肽的新抗原疫苗的多组分化学组合物
|
|
EP4392140A1
(en)
|
2021-08-24 |
2024-07-03 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
AU2023235112A1
(en)
|
2022-03-14 |
2024-10-17 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
JP2025541604A
(ja)
|
2022-11-02 |
2025-12-22 |
ティゲン・ファーマ・ソシエテ・アノニム |
リンパ球の拡大
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|
|
WO2026097062A1
(en)
|
2024-11-04 |
2026-05-07 |
Dana-Farber Cancer Institute, Inc. |
Genomic profiling of cells to monitor minimum residual disease
|